NewsUnichem Laboratories Shareholders Approve Independent Director Appointment and Related Party TransactionsUnichem Laboratories Shareholders Approve Independent Director Appointment and Related Party Transactions
Unichem Laboratories Limited completed its postal ballot process on 30th March 2026, with shareholders approving three key resolutions through remote e-voting. The resolutions included appointment of Dr. Swati Patankar as Non-Executive Independent Director and approval of material related party transactions with Unichem USA. All resolutions received over 99.99% approval, with the e-voting process conducted from 26th February to 27th March 2026 under scrutinizer supervision.
*this image is generated using AI for illustrative purposes only.
Unichem Laboratories Limited successfully completed its postal ballot process on 30th March 2026, with shareholders overwhelmingly approving three critical resolutions through remote e-voting. The pharmaceutical company announced the results in compliance with Regulation 44(3) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Postal Ballot Process Details
The postal ballot notice was issued on 5th February 2026, with the remote e-voting period commencing on Thursday, 26th February 2026 at 9:00 AM IST and concluding on Friday, 27th March 2026 at 5:00 PM IST. The cut-off date for determining voting eligibility was set as Friday, 20th February 2026, with a total of 24,132 shareholders registered as of that date.
| Parameter: | Details |
|---|---|
| Total Shareholders: | 24,132 |
| Cut-off Date: | 20th February 2026 |
| E-voting Period: | 26th February - 27th March 2026 |
| Total Outstanding Shares: | 7,04,05,750 |
Resolution Results
Resolution 1: Independent Director Appointment
Shareholders approved the appointment of Dr. Swati Patankar (DIN 06594600) as Non-Executive Independent Director for a five-year term effective 5th February 2026. This special resolution received exceptional support across all shareholder categories.
| Category: | Votes Polled | Votes in Favour | Approval % |
|---|---|---|---|
| Promoter Group: | 4,94,40,586 | 4,94,40,586 | 100.00% |
| Public Institutions: | 72,03,766 | 72,03,766 | 100.00% |
| Public Non-Institutions: | 67,096 | 66,547 | 99.18% |
| Total: | 5,67,11,448 | 5,67,10,899 | 99.999% |
Resolution 2: Related Party Transactions with Ipca-Unichem USA
The ordinary resolution approving material related party transactions between Ipca Laboratories Limited (holding company) and Unichem Pharmaceuticals USA Inc. (wholly owned subsidiary) was passed with strong minority shareholder support.
| Category: | Votes Polled | Votes in Favour | Approval % |
|---|---|---|---|
| Public Institutions: | 72,03,766 | 72,03,766 | 100.00% |
| Public Non-Institutions: | 67,096 | 66,547 | 99.18% |
| Total: | 72,70,862 | 72,70,313 | 99.992% |
Note: Promoter group abstained from voting due to interest in the resolution.
Resolution 3: Direct Related Party Transactions with Unichem USA
The third ordinary resolution concerning material related party transactions directly with Unichem USA, the wholly owned subsidiary, also received overwhelming approval from minority shareholders.
| Category: | Votes Polled | Votes in Favour | Approval % |
|---|---|---|---|
| Public Institutions: | 72,03,766 | 72,03,766 | 100.00% |
| Public Non-Institutions: | 62,596 | 62,047 | 99.12% |
| Total: | 72,66,362 | 72,65,813 | 99.992% |
Scrutinizer's Validation
Alwyn D'Souza of Alwyn Jay & Co., Company Secretaries, served as the appointed scrutinizer for the postal ballot process. The scrutinizer confirmed that all procedures were conducted in compliance with Section 108, Section 110, and Section 118(10) of the Companies Act, 2013, along with applicable SEBI regulations and MCA circulars.
The e-voting facility was provided by National Securities Depository Limited (NSDL), with votes being unblocked at 5:00 PM IST on 27th March 2026 in the presence of two independent witnesses. The scrutinizer's report validated that all three resolutions were deemed passed with requisite majority.
Corporate Governance Impact
The successful completion of this postal ballot process strengthens Unichem Laboratories' governance framework through the addition of an independent director and provides regulatory approval for strategic related party transactions. The overwhelming shareholder support, particularly from minority shareholders on related party matters, demonstrates confidence in the company's business strategy and transaction transparency.
The results and scrutinizer's report are available on the company's website at www.unichemlabs.com , stock exchange websites, and NSDL's e-voting portal for stakeholder reference.
Historical Stock Returns for Unichem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.93% | -4.88% | -13.91% | -37.76% | -57.40% | -4.24% |
What strategic initiatives or expansion plans might Dr. Swati Patankar's appointment as Independent Director enable for Unichem Laboratories' future growth?
How could the approved related party transactions with Unichem USA impact the company's market penetration and revenue growth in North American markets?
Will these governance changes and transaction approvals position Unichem Laboratories for potential acquisitions or partnerships in the pharmaceutical sector?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
